Cargando…

The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation

OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Wu, Yuxia, Kang, Deying, Wang, Jialiang, Hong, Qi, Le Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855762/
https://www.ncbi.nlm.nih.gov/pubmed/24324771
http://dx.doi.org/10.1371/journal.pone.0082324
_version_ 1782294963991609344
author Zhang, Xin
Wu, Yuxia
Kang, Deying
Wang, Jialiang
Hong, Qi
Le Peng,
author_facet Zhang, Xin
Wu, Yuxia
Kang, Deying
Wang, Jialiang
Hong, Qi
Le Peng,
author_sort Zhang, Xin
collection PubMed
description OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs. RESULTS: 226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%). CONCLUSION: Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It’s feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available.
format Online
Article
Text
id pubmed-3855762
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38557622013-12-09 The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation Zhang, Xin Wu, Yuxia Kang, Deying Wang, Jialiang Hong, Qi Le Peng, PLoS One Research Article OBJECTIVE: To explore external validity of randomized controlled trials (RCTs) of hypertension within China from the view of sample representation. METHODS: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central Register of Controlled Trials (CCTR) et al and advanced search strategies were used to locate hypertension RCTs as well as observational studies conducted in China during 1996 to 2009 synchronously. The risk of bias in RCTs and observational studies was assessed by two modified scales respectively, and then both types of studies with 3 or more grading scores were included for the purpose of evaluating of external validity. Following that the study characteristics relative to sample representation were extracted from RCTs and observational studies synchronously, and the later were taken as external references for validating sample representation of RCTs. RESULTS: 226 hypertension RCTs and 21 observational studies were included for final analysis. Comparing samples with observational studies, the mean age of samples within RCTs was 54.46 years, significantly lower than that of observational studies (66.35 years) (P=0.002). The average disease course in patients of RCTs was 3.89 years and grade III hypertensive patients accounted for 17%; both were lower than that of the observational studies (12.96 years, P<0.001; 34%, P=0.026 respectively). In addition, the proportions of patients with complications due to heart failure, stroke, diabetes, or coronary heart disease in RCTs were 8%, 5%, 12% and 11% correspondingly, all of which were significantly less than that of observational studies (11%, 18%, 17% and 29%). CONCLUSION: Sample characteristics within hypertension RCTs were significantly different from those in observational studies. The samples in most RCTs were under-represented. It’s feasible to take samples of observational studies as a mirror of the actual composition of hypertension patients in the real world, if the reporting of observational studies is abundant and available. Public Library of Science 2013-12-06 /pmc/articles/PMC3855762/ /pubmed/24324771 http://dx.doi.org/10.1371/journal.pone.0082324 Text en © 2013 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhang, Xin
Wu, Yuxia
Kang, Deying
Wang, Jialiang
Hong, Qi
Le Peng,
The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title_full The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title_fullStr The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title_full_unstemmed The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title_short The External Validity of Randomized Controlled Trials of Hypertension within China: from the Perspective of Sample Representation
title_sort external validity of randomized controlled trials of hypertension within china: from the perspective of sample representation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855762/
https://www.ncbi.nlm.nih.gov/pubmed/24324771
http://dx.doi.org/10.1371/journal.pone.0082324
work_keys_str_mv AT zhangxin theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT wuyuxia theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT kangdeying theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT wangjialiang theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT hongqi theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT lepeng theexternalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT zhangxin externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT wuyuxia externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT kangdeying externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT wangjialiang externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT hongqi externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation
AT lepeng externalvalidityofrandomizedcontrolledtrialsofhypertensionwithinchinafromtheperspectiveofsamplerepresentation